tremelimumab
Showing 1 - 25 of 105
Borderline Resectable Carcinoma, Biliary Tract Cancer Trial in Washington (Durvalumab, Tremelimumab, Gemcitabine)
Not yet recruiting
- Borderline Resectable Carcinoma
- Biliary Tract Cancer
- Durvalumab
- +4 more
-
Washington, District of ColumbiaLombardi Comprehensive Cancer Center, Georgetown University
Aug 24, 2023
Resectable Hepatocellular Carcinoma, Hepatocellular Carcinoma, Hepatocellular Cancer Trial in Boston (Durvalumab, Tremelimumab,
Not yet recruiting
- Resectable Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Boston, MassachusettsDana-Farber Cancer Institute
Jan 18, 2023
Metastatic, Melanoma, Non Small Cell Lung Cancer (NSCLC) Trial in Philadelphia (Radiotherapy, MEDI4736, Tremelimumab)
Active, not recruiting
- Metastatic
- +4 more
- Radiotherapy
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Jan 6, 2023
Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Not yet recruiting
- Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
- (no location specified)
Sep 27, 2022
NSCLC Trial (Durvalumab, Tremelimumab, Pemetrexed)
Not yet recruiting
- Carcinoma, Non-Small-Cell Lung
- Durvalumab
- +5 more
- (no location specified)
Aug 17, 2023
Hepatocellular Cancer, Hepatocellular Carcinoma, Metastatic Hepatocellular Carcinoma Trial run by the NCI (durvalumab,
Recruiting
- Hepatocellular Cancer
- +2 more
- durvalumab
- +4 more
-
Bethesda, MarylandNational Institutes of Health Clinical Center
Jan 20, 2023
Metastatic Breast Cancer Trial in New York (Brain radiotherapy or Stereotactic Radiosurgery, Tremelimumab, HER2 directed
Completed
- Metastatic Breast Cancer
- Brain radiotherapy or Stereotactic Radiosurgery
- +3 more
-
New York, New YorkMemorial Sloan Kettering Cancer Center
Aug 2, 2022
Pancreatic Cancer, Hepatocellular Cancer, Biliary Tract Cancer Trial in Edmonton (Durvalumab, Gemcitabine, Nab paclitaxel)
Not yet recruiting
- Pancreatic Cancer
- +3 more
- Durvalumab
- +5 more
-
Edmonton, Alberta, CanadaCross Cancer Institute
Feb 1, 2023
Unresectable Hepatocellular Carcinoma Trial (Durvalumab, Tremelimumab)
Available
- Unresectable Hepatocellular Carcinoma
- Durvalumab
- Tremelimumab
- (no location specified)
Aug 12, 2022
Recurrent Gynecological Cancer, Metastatic Cervical Cancer, Metastatic Ovarian Cancer Trial in Boston (Durvalumab, Tremelimumab,
Terminated
- Recurrent Gynecological Cancer
- +10 more
- Durvalumab
- +2 more
-
Boston, MassachusettsMartin King
Oct 4, 2022
Gastric Cancer, Microsatellite Instability Trial in Milan (Durvalumab, Tremelimumab)
Recruiting
- Gastric Cancer
- Microsatellite Instability
- Durvalumab
- Tremelimumab
-
Milan, ItalyFondazione IRCCS Istituto Nazionale dei Tumori di Milano
Aug 3, 2022
Endometrial Cancer, Endometrial Carcinosarcoma, Endometrial Carcinoma Trial in United States (Durvalumab, Tremelimumab)
Completed
- Endometrial Cancer
- +4 more
- Durvalumab
- Tremelimumab
-
Basking Ridge, New Jersey
- +6 more
Jan 3, 2023
Urothelial Carcinoma Trial in Amsterdam (Tremelimumab, Durvalumab, Paclitaxel)
Active, not recruiting
- Urothelial Carcinoma
- Tremelimumab
- +2 more
-
Amsterdam, NetherlandsAntoni van Leeuwenhoek Ziekenhuis
Jul 7, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8, Stage IVA Lung Cancer AJCC v8 Trial in Houston
Recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- +3 more
- Durvalumab
- +2 more
-
Houston, TexasM D Anderson Cancer Center
Oct 10, 2022
Nonsmall Cell Lung Cancer Trial in New York (Durvalumab, Tremelimumab)
Not yet recruiting
- Nonsmall Cell Lung Cancer
- Durvalumab
- Tremelimumab
-
New York, New YorkColumbia University Irving Medical Center
Apr 29, 2022
BRCA1 Gene Mutation, BRCA2 Gene Mutation, Ovarian Serous Adenocarcinoma Trial in Buffalo, New York (biological, other, drug)
Active, not recruiting
- BRCA1 Gene Mutation
- +5 more
- Durvalumab
- +3 more
-
Buffalo, New York
- +1 more
Jan 20, 2023
Metastatic Melanoma Trial in Boston (Tremelimumab, MEDI3617)
Active, not recruiting
- Metastatic Melanoma
- Tremelimumab
- MEDI3617
-
Boston, Massachusetts
- +1 more
Mar 22, 2022
Hepatocellular Carcinoma Trial in Toronto, Milan, Pamplona (Tremelimumab)
Not yet recruiting
- Hepatocellular Carcinoma
- Tremelimumab
-
Toronto, Ontario, Canada
- +2 more
Jun 27, 2022
Mesothelioma Trial in Houston (MEDI4736, Tremelimumab, no other name)
NSCLC, NSCLC Stage IV Trial in Madison (Durvalumab, Tremelimumab, Stereotactic Body Radiotherapy)
Active, not recruiting
- Non-small Cell Lung Cancer
- Non-small Cell Lung Cancer Stage IV
- Durvalumab
- +2 more
-
Madison, WisconsinUniversity of Wisconsin Carbone Cancer Center
Sep 21, 2022
Bladder Cancer, High-Risk Cancer, Tremelimumab Trial in Vancouver (Tremelimumab)
Recruiting
- Bladder Cancer
- +4 more
- Tremelimumab
-
Vancouver, British Columbia, CanadaVancouver General Hospital
Nov 3, 2021
Hepatocellular Carcinoma, Cirrhosis, Portal Hypertension Trial in Cincinnati (Durvalumab, Tremelimumab, Liver Transplant)
Recruiting
- Hepatocellular Carcinoma
- +2 more
- Durvalumab
- +2 more
-
Cincinnati, OhioUniversity of Cincinnati
Dec 8, 2021
Germ Cell Tumor, Nonseminomatous Germ Cell Tumor, Seminoma Trial in United States (Durvalumab, Tremelimumab)
Active, not recruiting
- Germ Cell Tumor
- +5 more
- Durvalumab
- Tremelimumab
-
Basking Ridge, New Jersey
- +6 more
May 2, 2022